title: Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis.
abstract: OBJECTIVE
  To assess the impact of household smoking and palivizumab prophylaxis on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm (32-35 weeks' gestational age) infants.
  
  
  METHODS
  Familial smoking and other RSV risk factor data from the FLIP, FLIP-2 and IMpact studies and datasets from France, Germany and Italy, together with palivizumab prophylaxis data from the FLIP-2 and IMpact studies, were analysed using cross-correlation and Bayesian meta-analytical modelling employing Markov Chain Monte Carlo sampling.
  
  
  RESULTS
  There were 2.35 times (95% confidence interval [CI] 1.37-4.02) as many hospitalisations amongst infants from smoking compared with those from non-smoking families. Among non-prophylaxed infants, there were 2.53 times (95% CI 1.27-4.94) as many RSV hospitalisations from smoking than from non-smoking families and that excess hospitalisation was reduced to 1.03 times (95% CI 0.38-2.99) amongst prophylaxed infants. Familial smoking correlates significantly (p < 0.01) with other RSV risk factors: positive correlation with number of school-age siblings, history of family atopy, family wheeze and gestational age; negative correlation with birth weight and breast feeding.
  
  
  CONCLUSIONS
  Late-preterm infants from smoking families appear to be at heightened risk for severe RSV infection requiring hospitalisation of which the risk may be reduced with RSV prophylaxis.
authors: Neonatology Service, Hospital Clínic, Institut Clínic de Ginecologia Obstetricia I Neonatologia, Barcelona, Spain.
authors: Xavier
authors: X
authors: Carbonell-Estrany
authors: John R
authors: JR
authors: Fullarton
authors: Katherine L
authors: KL
authors: Gooch
authors: Pamela G
authors: PG
authors: Vo
authors: Jose
authors: J
authors: Figueras-Aloy
authors: Marcello
authors: M
authors: Lanari
authors: Jean-Bernard
authors: JB
authors: Gouyon
authors: Johannes G
authors: JG
authors: Liese
mesh_terms: D019072:Antibiotic Prophylaxis; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage; D015331:Cohort Studies; D005191:Family Characteristics; D005865:Gestational Age; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000453:epidemiology / Q000517:prevention & control; D000069455:Palivizumab; D010290:Parents; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology* / Q000517:prevention & control; D012307:Risk Factors; D014028:Tobacco Smoke Pollution / Q000009:adverse effects* / Q000706:statistics & numerical data
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D014028:Tobacco Smoke Pollution; D000069455:Palivizumab